Elekta and Varian settle patent litigation

STOCKHOLM, April 3, 2017 – Elekta (EKTA-B.ST) and Varian Medical Systems (NYSE: VAR) have reached a confidential settlement agreement to end ongoing patent litigation involving technology used for radiation oncology and the treatment of cancer. Varian and Elekta resolved the multi-year disputes in the United States, Germany, and the United Kingdom, including the suit brought by Elekta AB and William Beaumont Hospital, with no payments exchanged by the plaintiffs and defendants and no future financial obligations. The two companies have been in litigation since 2015.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director Investor Relations, Elekta AB
Tel: +46 8 587 25 415, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 22:30 CET on April 3, 2017. (REGMAR)

About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com 

Tags: